PAS
LNAI

Point72 Asia (Singapore)’s Lunai Bioworks LNAI Stock Holding History

Point72 Asia (Singapore)’s Portfolio LNAI Stock Details LNAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-693
Closed -$16K – 1189
2025
Q2 		$16K Buy
+693
New +$19.3K ﹤0.01% 759
2024
Q2 		– Sell
-23
Closed -$4.92K – 1424
2024
Q1 		$4.92K Buy
+23
New +$6.2K ﹤0.01% 1019

Other funds holding LNAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Point72 Asia (Singapore)'s LNAI Position: Q3 2025 in Review

Point72 Asia (Singapore) sold out of Lunai Bioworks (LNAI) in Q3 2025, closing a stake of 693 shares — an estimated $16K sold.

Point72 Asia (Singapore) first reported a position in LNAI in Q1 2024 and held it in 2 quarters. The position peaked at $16K in Q2 2025. 20 funds tracked by Wall St. Rank hold LNAI as of Q3 2025.

  • Point72 Asia (Singapore) reported no remaining Lunai Bioworks position as of Q3 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 693 Lunai Bioworks shares in Q3 2025, an estimated $16K.
  • Point72 Asia (Singapore) first reported a position in Lunai Bioworks in Q1 2024 and held it in 2 quarters.
  • Point72 Asia (Singapore)'s Lunai Bioworks position peaked at $16K in Q2 2025.
  • 20 funds tracked by Wall St. Rank held Lunai Bioworks as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.